Is BioSante in line for a Big Pharma buyout?

BusinessWeek's Gene Marcial sized up BioSante Pharmaceutical's pipeline and concluded that its late stage therapy for sexual dysfunction in menopausal women could make it a prime candidate for a buyout. LibiGel began a second Phase III trial recently while data from the first late-stage efficacy study is due out in 2009.

In Marcial's view, BioSante is lining up for a piece of a multibillion-dollar market. And then BioSante did bring in Deutsche bank to assess its strategic alternatives--usually a dead giveaway that a good offer would receive welcoming smiles.

- read the column from BusinessWeek

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.